← Back to Search

Virus Therapy

CPI-RSV-F Vaccine (BLB-201) for Respiratory Syncytial Virus Infection

Phase 1
Waitlist Available
Led By Paul Spearman, MD
Research Sponsored by Blue Lake Biotechnology Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 15, and day 29
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a nasal vaccine called BLB-201 in healthy adults aged 18-59 and 60-75. The vaccine uses a modified virus to help the immune system learn to fight infections. The study aims to see if the vaccine is safe and effective in these age groups.

Eligible Conditions
  • Respiratory Syncytial Virus Infection
  • Respiratory Syncytial Virus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 15, and day 29
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 15, and day 29 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Solicited Adverse Events
Unsolicited Adverse Events
Secondary study objectives
Serious Adverse Events through trial completion
Serious adverse events, new-onset chronic medical conditions, and adverse events of special interest
Serum IgG titers to RSV protein

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Group 2, older adult cohort (age 60-75)Experimental Treatment1 Intervention
BLB-201 administered as a single dose of 10\^7.5 PFU by intranasal route on Day 1
Group II: Group 1, young adult cohort (age 18-59)Experimental Treatment1 Intervention
BLB-201 administered as a single dose of 10\^7.5 PFU by intranasal route on Day 1
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CPI-RSV-F Vaccine (BLB-201)
2022
Completed Phase 1
~30

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Blue Lake Biotechnology Inc.Lead Sponsor
1 Previous Clinical Trials
137 Total Patients Enrolled
Paul Spearman, MDPrincipal InvestigatorChildren's Hospital Medical Center, Cincinnati
4 Previous Clinical Trials
532 Total Patients Enrolled
~9 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top